<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124387">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01915173</url>
  </required_header>
  <id_info>
    <org_study_id>2012-P-000409</org_study_id>
    <secondary_id>IND 117358</secondary_id>
    <nct_id>NCT01915173</nct_id>
  </id_info>
  <brief_title>Response to Supplement and Placebo in GERD</brief_title>
  <official_title>Response to Supplement and Placebo in GERD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of a widely available over the
      counter supplement marketed for heartburn symptoms on symptoms and health-related quality of
      life in patients with gastroesophageal reflux disease (GERD).  This study is designed as a
      pilot trial to assess safety and feasibility and to provide preliminary estimates of effect
      sizes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety - number of major and minor adverse events</measure>
    <time_frame>2 week follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>No major adverse events (as defined by FDA criteria) attributed to the study intervention and no statistically significant increase in minor adverse events between the intervention and placebo arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with a 50% or greater decrease in heartburn symptom severity</measure>
    <time_frame>Second week of the trial compared to pre-trial baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on daily symptom diary scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent improvement in disease-specific and overall quality of life</measure>
    <time_frame>Two weeks (baseline to follow-up)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Gastroesophageal Reflux Disease (GERD)</condition>
  <condition>Heartburn</condition>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Supplement + Expanded Interview</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplement, 2 tablets sublingually 3 times a day for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Standard Interview</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 2 tablets sublingually 3 times a day for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement + Standard Interview</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplement, 2 tablets sublingually 3 times a day for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Expanded Interview</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 2 tablets sublingually 3 times a day for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supplement</intervention_name>
    <description>Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C</description>
    <arm_group_label>Supplement + Expanded Interview</arm_group_label>
    <arm_group_label>Supplement + Standard Interview</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lactose tablets</description>
    <arm_group_label>Placebo + Standard Interview</arm_group_label>
    <arm_group_label>Placebo + Expanded Interview</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Expanded Interview</intervention_name>
    <arm_group_label>Supplement + Expanded Interview</arm_group_label>
    <arm_group_label>Placebo + Expanded Interview</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard Interview</intervention_name>
    <arm_group_label>Placebo + Standard Interview</arm_group_label>
    <arm_group_label>Supplement + Standard Interview</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult humans age 18-80.

          -  Fluency in written and spoken English.

          -  Heartburn symptoms 3 or more days per week for the past month.

        Exclusion Criteria:

          -  Individuals taking a proton pump inhibitor (PPI) or H2 receptor blocker with a dose
             change within 2 weeks of the initial study visit.

          -  Individuals with Crohns disease, systemic sclerosis, known active ulcer disease,
             gastric cancer, Barrett's esophagitis

          -  Significant pain or difficulty with swallowing

          -  Heavy alcohol use (defined by &gt; 6 drinks/week for women and &gt; 13 drinks/week for men)

          -  Concurrent pregnancy

          -  Dementia

          -  Uncontrolled psychiatric disease

          -  Individuals unable to complete a paper symptom diary for 6 of 7 days prior to their
             baseline visit

          -  Subjects whose symptoms are predominantly dyspeptic more than heartburn or reflux

          -  Subjects who have used homeopathy for GI symptoms or have received constitutional
             homeopathic treatment within the past 2 weeks

          -  Subjects taking herbal products or other supplements for GERD or dyspepsia related
             symptoms (includes peppermint oil)

          -  Subjects who have taken &gt; 12 doses of NSAIDS within the prior 30 days (aspirin â‰¤ 325
             mg daily is allowed)

          -  Subjects with lactose intolerance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Dossett, MD, PhD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroesophageal reflux disease (GERD)</keyword>
  <keyword>Heartburn</keyword>
  <keyword>Dyspepsia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
